Kathleen Mullane

Kathleen Mullane is a Clinical Professor in the Department of Medicine-Infectious Diseases at the University of Chicago. Her work focuses on infectious diseases, particularly in immunocompromised populations, including hematopoietic cell transplant recipients and cancer patients. She specializes in antimicrobial therapy, clinical trials for antivirals and antifungals, and management of Clostridium difficile infections.

Her research spans drug development for infections like cytomegalovirus, respiratory syncytial virus, and pneumococcal infections. She has contributed to studies on vaccine efficacy in transplant recipients and antiviral strategies during pandemics, such as the mRNA-1273 trial for SARS-CoV-2. Her work emphasizes translational research with a focus on improving outcomes in high-risk patient groups.

Publications highlight her leadership in clinical trials evaluating treatments like remdesivir for severe infections and isavuconazole for mucormycosis. She has explored biomarkers for invasive aspergillosis and neutrophil dysfunction in immunocompromised patients. Her work bridges laboratory findings with clinical practice, addressing urgent challenges in infectious disease management.